CHOONG ANG VACCINE LABORATORY

072020 KRX Pharmaceuticals Pharmaceuticals
KOSDAQ
₩9,210.00
-0.22%
Delayed · cached 15 min

Fair value analysis

072020
CHOONG ANG VACCINE LABORATORY
PharmaceuticalsPharmaceuticals
₩9,210.00
Close used for this calculation
₩7,004.64Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
30/100
Profitability8/25
Returns3/25
Balance Sheet15/25
Efficiency4/25
Growth0/25
Weak
Quality radar
30Prof.8/25Ret.3/25Eff.4/25B.Sht15/25Growth0/25

Consensus fair value

₩7,004.64
Above FV
▼ -23.9% against the close used
Model range ₩1,754.29 – ₩9,616.20
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₩1,754.29Fair value₩7,004.64Bull₩9,616.20
FairClose
52-week traded range
52W low ₩9,010.0052W high ₩9,380.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

CHOONG ANG VACCINE LABORATORY closed at ₩9,210.00, 31.5% above the consensus fair value of ₩7,004.64 drawn from 7 valuation models.

Financial DNA score 30/100 — Weak. P/E of 22.2x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₩7,778.15
-15.5%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩9,616.20
+4.4%
√(22.5 × EPS × BVPS)
EPS=415, BVPS=9903.23
P/E Fair Value
₩8,300.00
-9.9%
EPS × 20x (sector P/E)
EPS=415, Sector P/E=20x
EV/EBITDA
₩3,141.33
-65.9%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=4.28B
Book Value (P/B)
₩1,754.29
-81.0%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=9903.23, ROE=4.2%, g=3%, r=10%
Reverse DCF
₩9,210.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 8.6% | Historical: 0%
Margin of Safety
₩6,423.59
-30.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=8564.78, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.